Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEND001 in Idiopathic Pulmonary Fibrosis
NCT06081621Phase 2Completed
- Sponsor
- Regend Therapeutics
- Start
- Dec 2023
- Primary completion
- Mar 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in idiopathic pulmonary fibrosis (IPF) comparing REGEND001 with Placebo (2 arms). Primary endpoint: Area under the curve of DLCO measured values at 24 weeks. Started Dec 2023; status: completed.
02
Drugs
autologous bronchial basal cells
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT06081621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06081621.